arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Theriva Biologics, Inc.

TOVX

$0.23 0.00 (+0.22%) at close

17 Visible periods

26 Metrics

Absolute Benchmarks

Price Chart

Health

Poor

Bearish Absolute basis

auto_awesome

Analytical Summary

On an absolute basis, Theriva Biologics, Inc. shows weak fundamentals, weighed down by Return on Invested Capital and Interest Coverage. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $2.8M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -1137.1% ↗

FCF / Share $-1.38 ↗

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

17-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-23.74M

↑ +7.5% —

FCF / Share Free cash flow per share

$-1.38

↑ +89.0% —

Long-Term Debt Long-term obligations

$1.67M

↑ +1716.3% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Invested CapitalReturn on Invested Capital of -1137.1% is weak on an absolute basis (target > 10%)
Interest CoverageInterest Coverage of -394.28x is weak on an absolute basis (target > 5x)
FCF / Net IncomeFCF / Net Income of 0.70x is caution on an absolute basis (target > 1x)

Health Breakdown

Financial Health

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Jun 30, 2022 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗	FY 2011 Dec 31, 2011 10-K ↗	FY 2010 Dec 31, 2010 10-K ↗	FY 2009 Dec 31, 2009 10-K ↗
EPS Growth YoY (%)	89.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	33.2% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	13.0% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	31.1% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-187.9% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	7.5% Fair ↑ Fair Improving Year-over-year change in net income	-39.8% Weak ↓ Weak Declining Year-over-year change in net income	6.8% Fair ↑ Fair Improving Year-over-year change in net income	-38.0% Weak ↓ Weak Declining Year-over-year change in net income	-42.1% Weak ↓ Weak Declining Year-over-year change in net income	34.4% Excellent ↑ Excellent Improving Year-over-year change in net income	-14.5% Weak ↓ Weak Declining Year-over-year change in net income	11.9% Fair ↑ Fair Improving Year-over-year change in net income	44.3% Excellent ↑ Excellent Improving Year-over-year change in net income	37.7% Excellent ↑ Excellent Improving Year-over-year change in net income	-121.1% Weak ↓ Weak Declining Year-over-year change in net income	-60.6% Weak ↑ Weak Improving Year-over-year change in net income	27.8% Excellent ↑ Excellent Improving Year-over-year change in net income	-109.4% Weak Weak Year-over-year change in net income	-376.3% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	89.0% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	57.8% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	4.8% Caution ↑ Caution Improving Year-over-year change in free cash flow	-18.3% Weak Weak Year-over-year change in free cash flow	-65.3% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Jun 30, 2022 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗	FY 2011 Dec 31, 2011 10-K ↗	FY 2010 Dec 31, 2010 10-K ↗	FY 2009 Dec 31, 2009 10-K ↗
Effective Tax Rate (%) (%)	—	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	8.2% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	6.8% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—	—	—	—	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
Profit Margin (%) (%)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-65.5% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-645%)	—
FCF Margin (%) (%)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-44.3% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	0.70x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.66x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.05x Fair → Fair Stable Free cash flow relative to reported net income Optimal: > 1x	0.98x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.21x Good → Good Stable Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.29x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	1.35x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	1.04x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.63x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.52x Weak → Weak Stable Free cash flow relative to reported net income Optimal: > 1x	0.35x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.68x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Jun 30, 2022 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗	FY 2011 Dec 31, 2011 10-K ↗	FY 2010 Dec 31, 2010 10-K ↗	FY 2009 Dec 31, 2009 10-K ↗
Return on Invested Capital (%)	-1137.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-28637.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-12143.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-35.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-22.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	168.4% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	-679.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-81.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	1386.2% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-806.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-201.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-169.5% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-64.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	—	—
Return on Capital (%) (%)	-62.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-74.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-38.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-28.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-20.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-120.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-90.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-58.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-139.4% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-174.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-132.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-107.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	-75.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	—	—	—	-34.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-333%)	-22.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-253%)	210.7% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1305%)	—	-78.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-622%)	—	—	-272.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1917%)	-207.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1480%)	-80.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-639%)	-131.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-973%)	-115.4% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-870%)	-47.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-419%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Jun 30, 2022 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗	FY 2011 Dec 31, 2011 10-K ↗	FY 2010 Dec 31, 2010 10-K ↗	FY 2009 Dec 31, 2009 10-K ↗
Debt to Equity (x)	—	—	—	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-99%)	—	—	—	—	—	—	—	—	—	—	—	—	—
Interest Coverage (x)	-394.28x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Net Debt (USD)	$-11.38M	$-11.52M	$-22.95M	$-50.21M	$-67.33M	$-6.23M	$-15.04M	$-28.92M	$-17.12M	$-19.05M	$-20.82M	$-17.52M	$-14.62M	$-9.95M	—	—	—
Debt / EBITDA (x)	-0.07x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.00x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.01x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.01x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—	—	—	—	—	—	—	—	—	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Jun 30, 2022 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗	FY 2011 Dec 31, 2011 10-K ↗	FY 2010 Dec 31, 2010 10-K ↗	FY 2009 Dec 31, 2009 10-K ↗
Basic EPS, GAAP (USD)	$-2.08	$-19.03	$-28.50	$-32.75	$-47.50	$-16.50	—	—	—	—	—	—	—	—	—	—	—
Free Cash Flow per Share (USD)	$-1.38	$-12.56	$-29.80	$-31.31	$-26.47	$-16.01	—	—	—	—	—	—	—	—	—	—	—
Book Value per Share (USD)	—	—	—	$8.90	$117.80	$-4.07	$2.71	$27.56	$-10.19	$0.82	$4.42	$3.29	$6.54	$7.34	$5.64	$3.83	—
Tangible Book Value per Share (USD)	—	—	—	$5.31	$72.26	$-4.07	$2.71	$27.56	$-10.19	$0.82	$4.42	$3.29	$6.54	$7.34	$5.64	$3.83	—
Basic Weighted Avg Shares (shares)	12.14M	1.35M	644,281	613,093	487,500	760,454	—	—	—	—	—	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Jun 30, 2022 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗	FY 2011 Dec 31, 2011 10-K ↗	FY 2010 Dec 31, 2010 10-K ↗	FY 2009 Dec 31, 2009 10-K ↗
Working Capital (USD)	$7.45M	$8.70M	$20.66M	$40.41M	$65.30M	$4.97M	$11.15M	$26.13M	$8.15M	$1.81M	$14.76M	$9.48M	$15.19M	$12.07M	$6.71M	$3.04M	—
LT Debt (USD)	$1.67M	$92.00K	$162.00K	$221.00K	—	—	—	—	—	—	—	—	—	—	—	—	—
Total Equity (USD)	—	—	—	$56.39M	$62.22M	$-4.77M	$1.82M	$17.07M	$-1.50M	$3.85M	$16.05M	$9.56M	$15.23M	$13.03M	$7.06M	$3.58M	$3.54M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Jun 30, 2022 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗	FY 2011 Dec 31, 2011 10-K ↗	FY 2010 Dec 31, 2010 10-K ↗	FY 2009 Dec 31, 2009 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	$2.61M	—
Depreciation Expense (USD)	$108.00K	$137.00K	$135.00K	$85.00K	$87.00K	$201.00K	$240.00K	$272.00K	$245.00K	$157.00K	$72.00K	$20.00K	$43.00K	$63.00K	$144.00K	$346.00K	—
Net Income, GAAP (USD)	$-23.74M	$-25.65M	$-18.35M	$-19.68M	$-14.27M	$-10.04M	$-15.30M	$-13.37M	$-15.17M	$-27.25M	$-43.74M	$-19.78M	$-12.32M	$-17.07M	$-8.15M	$-1.71M	—
Operating Cash Flow (USD)	$-16.67M	$-16.94M	$-19.00M	$-19.08M	$-12.89M	$-12.17M	$-13.87M	$-17.28M	$-20.20M	$-27.90M	$-38.89M	$-16.08M	$-7.72M	$-8.92M	$-2.88M	$-1.15M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 17 years · 66 quarters

Theriva Biologics, Inc.

Analytical Summary

17-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Benchmarks unavailable

Compare TOVX with peers